For nearly four decades, when federal laws were unclear or left gaps in guidance, courts relied on agency interpretations to fill in the blanks. This principle, known as the Chevron deference, allowed regulatory agencies to shape policy and advance their priorities.
However, in a landmark decision this June, the Supreme Court overturned the Chevron doctrine. This ruling has significant implications for industries heavily regulated by federal agencies, including healthcare, and for regulators like the FDA, which may now face challenges in implementing and enforcing policies.
In a recent episode of 'The Top Line' podcast by Fierce Pharma, Project Farma’s Anshul Mangal sat down with Kevin Dunleavy to explore how this decision could reshape the biopharma landscape.
Interested in the full discussion? Tune in to 'The Top Line' podcast to hear the complete conversation and dive deeper into the implications of Chevron's overturn on the biopharma industry. Click here to listen now!